DESFERAL OSVERAL OSVERAL OSVERAL OSVERAL OSVERAL OSVERAL

Dose: 15 mg/kg/hr
Single Dose: 15 (15)
Frequency: As recommended.
Route: Cont. IV-inf
Instructions: Max. 80 mg/kg in 24 hrs.

Dose: 28.571 mg/kg
Single Dose: 29 (28.571)
Frequency: 24 hourly
Route: Intra Muscular
Instructions: Initial

Dose: 28.571 mg/kg
Single Dose: 29 (28.571)
Frequency: 24 hourly
Route: Intra Muscular
Instructions: Initial

Deferoxamine also known as Desferrioxamine. . It is of Semi Synthetic origin and belongs to Methanesulfonate. It belongs to Chelating Agent pharmacological group.The Molecular Weight of deferoxamine is 656.80.

deferoxamine is contraindicated in conditions like Renal impairment.

The severe or irreversible adverse effects of deferoxamine, which give rise to further complications include Hypotension, Hypotension.deferoxamine produces potentially life-threatening effects which include Cardiac arrhythmia, Tachypnea, Anaphylaxis, Hypoxemia, Hypoxemia. which are responsible for the discontinuation of deferoxamine therapy.The signs and symptoms that are produced after the acute overdosage of deferoxamine include Bradycardia, Hypotension, Loss of vision, Aphasia.The symptomatic adverse reactions produced by deferoxamine are more or less tolerable and if they become severe, they can be treated symptomatically, these include Redness, Allergy, Swelling, Hearing loss, Reduced visual acuity, Night blindness, Field defects, Pupillary abnormalities, Optic neuritis, Electro-oculographic abnormalities, Retinal pigmentary changes, Asymptomatic electro-retinographic abnormalities, Discomfort, Legcramps.

deferoxamine is primarily indicated in conditions like Acute iron poisoning, Aluminium related bone disease, Aluminium -related encephalopathy, Anaemia, Blood transfusion, Chronic iron overload, Haemochromatosis, Hemochromatosis, Iron poisoning, Ocular siderosis, Transfusion-related iron overlaod.

deferoxamine is known to interact with other drugs, the details of drug interactions is as follows:DrugDetailsSeverityOnsetManagementAmisulprideEpoetinFolic AcidMethotrimeprazine (Maleate)ProchlorperazinePromazine (HCl)Sulpiride These interactions are sometimes beneficial and sometimes may pose threats to life. Always consult your physician for the change of dose regimen or an alternative drug of choice that may strictly be required.

Colorimetric measurement of iron concentrations in any body fluid. Spot Testing of Urine for drugs.

Drug should not be given to Pregnant Mothers.If prescribing authority justifies the benefits of the drug against the possible damages he/she should reevaluate them and consult the reference material and previous studies.

Inj Store in a well closed container. Refrigeration is recommended. Protect from Sunlight.

Desferrioxamine should be given with caution in patients with impaired renal function.The urinary excretion of iron should be regularly monitored during treatment & periodic opthalmological (visual) & audiological (hearing) examinations are recommended for patients on long term therapy. Monitoring of cardiac function is also recommended for patients receiving combined treatment with ascorbic acid. Avoid high doses in children with low ferritin levels, because it cause the growth retardation, therefore regular checks on weight and height are recommended for children. An increased susceptibility to infection has been reported, if infectrion is suspected, treatment with desferroxamine should be stopped and should start appropriate antimicrobial treatment.